Accessibility Menu
Burzynski Research Institute logo

Burzynski Research Institute(OTC) BZYR

Market Cap$687.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1990)-83%
5 Year-85%
1 Year-89%
1 Month-13%
$0.01
+0%
+0.00Today
Burzynski Research Institute last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-28
Burzynski Research Institute stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.65%USD 0.012026-07-17
1 month-12.82%USD 0.012026-06-26
3 month-61.25%USD 0.012026-04-29
Year to date-72.61%USD 0.022025-12-29
1 year-89.1%USD 0.052025-07-24
3 year-92.58%USD 0.072023-07-27
5 year-84.61%USD 0.032021-07-23
Since inception-82.56%USD 0.031990-10-03

Burzynski Research Institute Financials at a Glance

Market Cap

$687.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.29M

EPS (TTM)

-$0.01

P/E Ratio

-0.53

Dividend

$0.00

Beta (Volatility)

0.07 (Low)

Price

$0.01

Volume

100,000

Open

$0.00

Previous Close

$0.01

Daily Range

$0.00 - $0.01

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

May 18, 2026

BZYR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Burzynski Research Institute

Burzynski Research Institute develops drugs for cancer treatment research. Its main focus is on antineoplaston compounds, which aim to slow cancer cell growth. The company’s work targets patients with difficult-to-treat brain tumors.

What’s in the Burzynski Toolbox?

  • Antineoplaston drugs: Experimental compounds designed to inhibit cancer cell growth; 0% of revenue as no sales.
  • Consulting services: Advice on cancer research and drug development; 0% of revenue as no sales.
  • Patent licensing: Exclusive rights to develop and commercialize antineoplaston drugs in the US and Canada; 0% of revenue.

Growth and Expansion: The Road Less Traveled

  • Signed new exclusive license agreement with Dr. Burzynski for antineoplaston patents in May 2023.
  • Amended research funding and royalty agreements in 2023 to align with new licensing terms.
  • Received orphan drug designations from the FDA for brain tumor treatments in prior years.
  • No acquisitions, product launches, or global market entries reported since inception.

What Makes Burzynski Stand Out?

It holds exclusive rights to a niche class of experimental cancer drugs. All clinical trials are on hold, limiting commercial activity and market reach.

Five Things You Need to Know

  • Revenue was $0 in QQ2 2026, unchanged from QQ2 2025 and QQ2 2024.
  • Operating loss was $-333,867 in QQ2 2026, a 9.7% improvement year-on-year.
  • Cash used in operations was $-94,907 in QQ2 2026, an improvement of 35.9% from QQ2 2025.
  • Cash balance was $931 as of August 31, 2025, with no external financing.

Bottom Line

Burzynski remains focused on experimental cancer drug research, with all funding from its founder. The company’s future depends on regulatory progress and continued financial support.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Stanislaw R. Burzynski, MD, PhD

Website

www.burzynskiclinic.com

Headquarters

Houston, TX 77055, US

BZYR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2073.54%

Return on Capital

N/A

Return on Assets

-56820.22%

Earnings Yield

-1.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$687.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

131.45M

Volume

100.00K

Avg. Volume

14.02K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.29M

EBITDA

-$1.29M

Operating Cash Flow

-$1.01M

Capital Expenditure

-$4.00

Free Cash Flow

-$1.01M

Cash & ST Invst.

$2.17K

Total Debt

$0.00

Burzynski Research Institute Performance Analysis

Burzynski Research Institute annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-02-28USD 0N/A
20232023-02-28USD 0N/A
20242024-02-29USD 0N/A
20252025-02-28USD 0N/A
Burzynski Research Institute sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-02-28N/A
Q12025-05-31N/A
Q22025-08-31N/A
Q32025-11-30N/A
Burzynski Research Institute annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-02-28USD -0.01N/A
20232023-02-28USD -0.01-5.4%
20242024-02-29USD -0.0145.7%
20252025-02-28USD -0.013.9%
Burzynski Research Institute sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-02-2818.5%
Q12025-05-31-13.6%
Q22025-08-31N/A
Q32025-11-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$687.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$687.60K

N/A

Employees

1

N/A

Net Income

-$328.86K

+6.6%

EBITDA

-$328.86K

+6.6%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$2.17K

+253.2%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-568.20%

N/A

Return on Invested Capital

19.11%

N/A

Free Cash Flow

-$823.11K

-513.7%

Operating Cash Flow

-$823.11K

-513.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
THERTheralink Technologies, Inc.
$0.00+0.00%
BIXTBioxytran, Inc.
$0.02+7.14%
BVAXFBioVaxys Technology Corp.
$0.11+0.00%
CPMVMosaic ImmunoEngineering Inc.
$0.55+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About BZYR

What is the current price of Burzynski Research Institute?

Burzynski Research Institute is trading at $0.01 per share.

What is the 52-week range for Burzynski Research Institute?

Over the past 52 weeks, Burzynski Research Institute has traded between $0.00 and $0.05.

How much debt does Burzynski Research Institute have?

As of the most recent reporting period, Burzynski Research Institute reported total debt of $0.00.

How much cash does Burzynski Research Institute have on hand?

Burzynski Research Institute reported $2.17K in cash and cash equivalents in its most recent financial results.

What is Burzynski Research Institute’s dividend yield?

Burzynski Research Institute does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services